Also Read: JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability. The FDA is reviewing a supplemental application for Vtama cream as a potential ...
we are excited for VTAMA cream to benefit from Organon’s commercial scale. We believe they have the capabilities and reach to ensure patients globally can access this important medicine.” ...
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of $18.00. Terence Flynn’s rating is based on the potential and ...
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Some results have been hidden because they may be inaccessible to you